Adenovirus infection in immunocompromised patients

M.D. Anderson Cancer Center — PHASE1

Jessie L. Alexander — PHASE1, PHASE2

Harvoni: FDA approved

HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin

M.D. Anderson Cancer Center — PHASE1

Descovy: FDA approved

DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg.

Children's Hospital Medical Center, Cincinnati — PHASE2

Cystaran: FDA approved

Treatment of corneal cystine crystal accumulation in patients with cystinosis

National Institute of Allergy and Infectious Diseases (NIAID)

Neutrexin: FDA approved

Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.

Cytovene: FDA approved

Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.